Eris Lifesciences forms JV with MJ Biopharm to enter insulin segment
Drug maker Eris Lifesciences on Friday said it has formed a joint venture with Mumbai-based MJ Biopharm to enter the insulin segment.
Eris MJ Biopharm, the 70:30 joint venture (with Eris holding a 70 per cent stake), would primarily engage in marketing and distribution of human and analogue insulin including Aspart, Glargine and Lispro and GLP-1 agonists and potentially other biopharma products in India.
MJ will be responsible for the development, manufacturing and supply of these products to the JV.
“With the formation of this JV with MJ, we are taking our commitment a step further. Over the next 10-15 years, growth in diabetes care will be driven by DPP4-SGLT2 combinations, Insulin Analogues and GLP1 agonists, given the superior clinical evidence on their ability to provide better glycemic control, cardio-renal protection, and weight management,” Eris Lifesciences Chairman and Managing Director Amit Bakshi said in a statement.
With the formation of this JV, the company will add Human Insulin, Analogues and GLP-1 agonists to its portfolio, which along with other devices makes it a full-service player in diabetes care, he added.
“I am excited about this collaboration with Eris and we look forward to expand the breadth and depth of the Insulin market in India,” MJ Biopharm Managing Director Amol Shah stated.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
